Fresh off the acquisition of metabolic medicines developer Metsera, Pfizer is again turning to dealmaking to expand its obesity drug pipeline, this time picking up an experimental oral ...
The Trump administration’s position on drug prices is that Americans pay too much while other countries don’t pay nearly enough. A new trade deal with the United Kingdom is addressing ...
Regeneron Pharmaceuticals is committing $150 million to begin an alliance on a Tessera Therapeutics gene-editing medicine nearing the clinic as a potential treatment for a rare disease ...
Light chain amyloidosis is not cancer, but cancer drugs are this rare disease’s standard of care. The patient need for new treatment options has sparked R&D efforts at biotech and big ...
